Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic acid to prevent sodium valproate-induced hepatic damage in neurological patients
IRCT20181228042156N1Phase 3Completed
- Sponsor
- Zabol University of Medical Sciences
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ursodeoxycholic acid in migraine, epilepsy and bipolar disorder (BD), sponsored by Zabol University of Medical Sciences. Started Jan 2019; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
migraineepilepsybipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20181228042156N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181228042156N1.